MedPath

The effect of rosuvastatin in multiple sclerosis

Phase 2
Conditions
Multiple sclerosis.
Multiple sclerosis
Registration Number
IRCT20210211050323N3
Lead Sponsor
Hamedan University of Medical Sciences
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Pending
Sex
All
Target Recruitment
40
Inclusion Criteria

History of multiple sclerosis at least one year ago
Radiographic findings of magnetic resonance imaging ( MRI ) consistent with the clinical diagnosis of multiple sclerosis
No other concomitant inflammatory disease
Bad cholesterol levels (low-density lipoprotein) less than 130 mg / dL
No pregnancy and lactation
The consistency of the main treatment of patients and the use of a specific type of drug
Do not take medications other than standard treatments for multiple sclerosis that alter the levels of the factors under consideration.
Do not use any combination with antioxidant effects in the past month.

Exclusion Criteria

Existing evidence-based on increased patient disability
Consumption of any combination, or drugs with antioxidant effects except prescription drugs
The existence of any cognitive or behavioral disorders with an effect on the patient's cooperation

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Cytochrome b-245 beta chain (CYBB) gene expression. Timepoint: Before the intervention and 3 months after the start of the intervention. Method of measurement: Laboratory.
Secondary Outcome Measures
NameTimeMethod
Expanded Disability Status Scale (EDSS ) score. Timepoint: Before the intervention and 3 months after the start of the intervention. Method of measurement: Expanded Disability Status Scale (EDSS) questionnaire.
© Copyright 2025. All Rights Reserved by MedPath